Of 1.4 million women in the database during the study timeframe, 60246 (4%) were included in the study. The median age was 61 years (IQR 50-73), and the median follow-up was 2.6 years (IQR 1.6-4.2). Overall, 37% were treated with anticholinergics, 5% beta-3 agonists, 7% topical estrogen, 2% pelvic floor physical therapy, 26% saw a specialist, and 2% underwent third-line therapy. The median time to cessation of prescription filling was longer for beta-3 agonists versus anticholinergics (median 4.1 months [IQR 1-15] vs 3.6 months [IQR 1-10]; p <0.0001). The use of third-line therapies significantly increased over the study timeframe, from 1.1% to 2.2%(p<0.0001).
The authors found that the majority of patients do not continue filling prescriptions for OAB medications, and a minority of patients were referred for specialty evaluation. While third-line therapy use is increasing, it is used in a small proportion of women with OAB. Given these patterns, there may be an underutilization of specialist referral and other OAB therapies.
Presented by: Nicole A Dodge, MD, Department of Urology, Mayo Clinic Rochester, Minnesota
Co-Authors: Elizabeth B Habermann,2 John B Gebhart,3 Daniel S Elliott,1 Holly K Van Houten,2 Lindsey R Sangaralingham,2 Brian J Linder1
1Mayo Clinic Rochester Department of Urology,2Mayo Clinic Rochester Health Services Research,3Mayo Clinic Rochester Department of OB/GYN
Written by: Bilal Farhan, MD, Assistant Professor, Division of Urology, University of Texas, Medical Branch, Texas; @BilalfarhanMD, at the Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction Winter Meeting, SUFU 2020, February 25 - February 29, 2020, Scottsdale, Arizona